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ABSTRACT

Goswami, Tushar. M.S.B.M.E. Department of Biomedical, Industrial, and Human
Factors Engineering, Wright State University, 2019. Chondroitin Sulfate Hydrogels for
Total Wound Care Devices.

Chondroitin sulfate (CS) is a naturally occurring bio-polymer found in areas of high
cartilage in mammals. In directed applications, such as hydrogels, CS can be used to
impact keratinocyte growth cycles. In this work, CS based hydrogels were utilized to
accelerate wound healing and, in conjunction with a graphene sensor, monitor wound
fluid pH. The hydrogels were cast onto a graphene field effect transistor (GFET) to
obtain the benefits of the hydrogel wound healing capabilities, while also utilizing the pH
sensitivity of the graphene. Results showed that the hydrogel caused a fivefold increase in
cell size over the course of 5 days compared to the control, and accelerated keratinocyte
proliferation by an average of 81% when compared to a control. The GFET resistance
changed as a function of pH, however, the resulting pH response was parabolic. Further
investigation into pH sensitive 2D materials may be necessary in order to optimize and
fabricate a functional wound monitoring device.

iv

TABLE OF CONTENTS
1. Literature Review ............................................................................................................... 1
1.1.

Introduction .................................................................................................. 1

1.2.

Inflammatory Phase ............................................................................5

1.3.

The Proliferative Phase .....................................................................10

1.4.

The Maturation Phase .......................................................................13

1.5.

Chronic Wounds ...............................................................................14

1.6.

Chemical and Physical Biomarkers used in Current Biosensors ......16

1.7.

Current Bandages/Adhesives ............................................................20

1.8.

Zeolite (QuikClot) .............................................................................23

1.9.

Polyethylene Glycol (PEG) Based Wound Sealants .........................24

1.10.

Hyaluronic Acid Based Hydrogels ...................................................26

1.11.

Chondroitin Sulfate (CS) ..................................................................27

1.12.

Engineering Biosensor Devices Utilizing Graphene-Based Materials
...........................................................................................................34

1.12.1. Engineering Biomolecule Based Biosensors using Pristine
Graphene .........................................................................................36
1.13.

Mechanism of Injury (Combat/Civilian/Austere) .............................37

1.14.

Effectiveness and Evolution of Hemostatic Agents/Dressings .........39

2. Experimental ..................................................................................................................... 44

2.1.

Materials ...........................................................................................44

2.2.

Chondroitin Sulfate Methacrylate (CS-MA) Synthesis ....................45

2.3.

CS-MA Polyethylene Glycol (CS-MA-PEG) Hydrogel Synthesis ..46

2.4.

Characterization ................................................................................46
v

TABLE OF CONTENTS (CONTINUED)
2.5.

Graphene Growth ..............................................................................47

2.6.

GFET Chip Preparation ....................................................................47

2.7.

Graphene Transfer ............................................................................48

2.8.

GFET Definition ...............................................................................49

2.9.

GFET Surface Modification and Coating with Hydrogel .................49

2.10.

GFET Device Testing .......................................................................49

2.11.

Human Keratinocyte (HaCaT) Cell Culture ....................................50

2.12.

Flow Cytometry of Treated & Untreated HaCaT Cells ....................51

3. Results & Discussion ........................................................................................................ 51

4. Conclusions ............................................................................................................64
5. References ..............................................................................................................66

vi

LIST OF FIGURES
1. Representation of the Fibrinolytic System .......................................................................... 6
2. Representation of the Common Clotting Pathway .............................................................. 8
3. The Healing Time Frame .................................................................................................... 9
4. Representation of the Inflammatory Phase of Wound Healing ........................................ 10
5. Representation of the Proliferative Phase of Wound Healing .......................................... 11
6. Representation of the Maturation & Remodeling Phase of Wound Healing .................... 13
7. Representation of Chronic Wound Development ............................................................. 15
8. Demonstration of Immobilized Glucose Oxidase on the Sensing Surface ....................... 18
9. Chemical Structure of Neomycin Sulfate ......................................................................... 20
10. Chemical Structure of Polymyxin B Sulfate ..................................................................... 21
11. Chemical Structure of Bacitracin Zinc ............................................................................. 22
12. Composition of Zeolite Surface Configuration................................................................. 23
13. Chemical Structure of Polyethylene Glycol .................................................................... 24
14. Chemical Structure of Hyaluronic Acid ........................................................................... 26
15. Chemical Structure Denoting Sulfonation Differences in Chondroitin Sulfate A, C, D, E,
H, and K ............................................................................................................................ 28
16. Injection of GHK-Cu Increases Accumulation of GAG in the Wound Chamber............. 29
17. Regulation of Fibroblast Adhesion by Chondroitin Sulfate.............................................. 30
18. The Association of Chondroitin Sulfate in Wound Contraction ....................................... 32
19. Signaling Pathways of FAK and Src. Controlling Actin Cytoskeletal Rearrangement .... 33
20. Illustration of Graphene-Based sensors that can be Immobilized with Biomolecules at the
Receptor Surface ............................................................................................................... 35
21. Scheme 1 .......................................................................................................................... 52
22. FT-IR Spectra Illustrating Ester Carbonyl Stretching Due to Methacrylate Substitution 53
23. 1H NMR Spectra of a) Neat CS and b) CS-MA in D2O .................................................. 54

vii

LIST OF FIGURES (CONTINUED)
24. Scheme 2 ........................................................................................................................... 55
25. a) GFET Device Without Hydrogel Coating b) GFET Device with CS-MA-PEG
Hydrogel Coating ............................................................................................................. 57
26. Blank GFET Devices Average Change in Resistance as a Function of pH ...................... 57
27. Change in Resistance as a Function of pH of a CS-MA-PEG GFET Device ................... 60
28. TGA of CS-MA-PEG Hydrogels as a Function of pH ..................................................... 61
29. Flow Cytometry Results of Hydrogels Cell Cycle Response ........................................... 63

viii

LIST OF TABLES
1. Biomarkers for Wound Healing stem ............................................................................... 17
2. Evaluation of Cell Viability of PEG Based Hydrogels ..................................................... 25
3. Tissue Regeneration Studies Using Hyaluronic Acid ....................................................... 27
4. Current Graphene-Based Biosensors and their Biomolecular Targets ............................. 36
5. First, Second, and Third Generation Hemostatic Products CoTCCC Approved for
Battlefield Use .................................................................................................................. 38

ix

1. Literature Review
1.1 Introduction
Disruptions in the epidermal matrix lead to wounding, where trauma or disease are
the primary modes. Healing begins shortly after wounding occurs, and is comprised of
three phases: 1) inflammatory, 2) proliferative, and 3) maturation. Wound type depends on
wound progression through healing, leading to the development of two main
classifications, acute and chronic. Acute wounds heal in an orderly and efficient manner,
characterized by specific biological markers such as metalloproteinase enzymes and tissue
inhibitor of matrix metalloproteinases. In general, acute wounds last a maximum of 30
days, with normal healing completed in 5 to 10 days.1-4 Complications with any of the
wound healing phases leads to chronic wound development. Chronic wounds are
characterized by a prolonged presence and excess of biological markers, indicating an
incomplete process where healing now takes months instead of weeks. For Americans this
represents a significant healthcare impact: exceeding 40 billion dollars and effecting 6.5
million people, annually.5 This literature review covers biological events that occur in
wound healing, strategies employed to monitor and accelerate the wound healing process,
as well as presents evidence for efficacy for current hemostatic products, and determines
the evidence for translating this technology into the prehospital civilian use.
Wound care, historically, has been superficial at best; patients were treated with
compression packs to stop bleeding. Often times, these compression packs were made from

1

disused cloth, introducing pathogenic agents into the wound matrix. Present consumer
solutions include bandages, formed of polymeric composites and absorbent fibers, and
topical antibiotic ointments. These bandages serve as a barrier between the superficial
epidermis and environmental factors. The polymeric composites adhesive property allows
for the application of mechanical pressure over the wound surface, promoting clotting.
Absorbent fibrous components allow for wound fluid passage and containment. Topical
antibiotic ointments are used in concert with bandages; where their efficacy is derived from
their molecular constituents: neomycin sulfate, polymyxin B sulfate, and bacitracin zinc,
all antibiotic agents.6-8
Over time, treatment has progressed to include targeted biological therapies.
Adhesive bandage packs now include treatments derived from various biomaterials and
minerals, with biochemically and physiologically beneficial treatment mechanisms.8 Of
note are: neomycin sulfate, polymyxin B sulfate, bacitracin zinc, chondroitin sulfate, and
zeolite.
Chondroitin sulfate is a sulfated glycosaminoglycan (GAG), comprised of an
alternating chain of sugars (N-acetylgalactosamine and glucuronic acid). It is commonly
found as a part of a proteoglycan, attached to proteins.9 The alternating chains of sugars
allow for variable sulfonation, in mutable quantities and position, as evidenced by the
existence of chondroitin sulfate A, C, D, E, H, and K.10 In nature, it is found in cartilage,
as it provides compression resistance.11 Zeolite is a conglomerate consisting of hydrated
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aluminosilicates of sodium, potassium, calcium, and barium.12 Zeolite is readily hydrated
and dehydrated and functions as a cation exchanger and molecular sieve. Commercially, it
is sold as QuikClot, and facilitates the activation of clotting proteins.13
Biosensors are devices which utilize analytical methods to detect and quantify
signals related to biomolecular elements. They use transducers to generate a defined signal
from a sample.14-15 A typical biosensor system setup is composed of a bio-receptor in
conjunction with a transducer. The bio-receptor is utilized to recognize biomolecular
elements, for example: antibodies, enzymes, DNA, RNA, and cells.16 Signal detection by
the receptor occurs in various quantities and is transduced by: chemical, optical, physical,
thermal, or electrochemical phenomena into quantitative information for analytical
processing.17
Historically, advances in prehospital and operative care were facilitated through
developments from war and conflict, where the trauma lessons learned are translated to
civilian medicine.18-19 Since 2001, the beginning of the conflicts in Afghanistan and Iraq,
advances in trauma care have been made to mitigate morbidity and mortality based on more
than 52,000 United States (US) combat casualties.20 Technologies that have been translated
to the civilian sector include: external and internal hemorrhage control, coagulopathy,
acidosis, and blood component therapy.21-23
In spite of these translations, hemorrhage is still the leading cause of combat fatality
and, in the civilian sector, is the second leading cause of death after traumatic brain
3

injury.21,24-25 As a consequence, major research thrusts into hemorrhage control over the
last 15 years have focused on wounds that are potentially survivable.21 In civilian trauma
epidemiological studies conclusions were been made that early trauma deaths (from
immediately on scene to 24 hours after) due to hemorrhage are deemed survivable, only if
the necessary personnel and resources are on hand.24
Research into topical hemostatic agents has grown since 2000, where the majority
of research concludes their superior utility over plain gauze in controlling severe
hemorrhage.20 In addition to innovations in research, great strides have been made for
trauma related training for military personnel (i.e. when to use tourniquets and hemostatic
dressings) learning to control bleeding and prevent shock and fatality.22,23 Hemostatic
agents play an integral role in augmenting external hemorrhage control when the location
of bleeding is in a junctional region such as: the neck, axilla, and groin.
Due to the strides made in efficacy, hemostatic agents and dressings have been
adopted into Tactical Combat Casualty Care (TCCC) guidelines since 2003.20,25 In addition
to hemostatic dressings, pressure dressings, tourniquets, chest seals, and other pressure
utilizing systems are found in the military individual first aid kit.26 These systems have
played an integral role in successfully controlling extremity and compressible junctional
hemorrhage in US and North Atlantic Treaty Organization (NATO) military personnel.2728

With the continuing evolution of hemostatic product efficacy, limited information
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regarding how widespread combat casualty lessons learned for hemostatic dressings are
translated into civilian practice.29
1.2. Inflammatory Phase
Inflammation is a physiological phenomenon where the body’s white blood cells
provide protection from foreign microbial invasion or trauma.30 There are five cardinal
signs of inflammation: 1) heat, 2) pain, 3) redness, 4) swelling, and 5) loss of function. The
inflammatory process occurs immediately after living tissue has been broken.1
Physiological indicators for wound inflammation are coagulation, hemostasis, chemotaxis,
and increased vascular permeability. As in-vivo fluid begins to congeal, biochemical
gradients are created which are utilized by constituent cells to prevent exsanguination. In
general, the inflammatory phase mainly functions to maintain structural integrity of the
dermal domain and to provide an initiation matrix for other cells to utilize in the subsequent
phases of healing.1
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Cellular constituents in the inflammatory phase include: endothelial cells
and thrombocytes. Together, these cells regulate the fibrinolysis process, which is
represented in Figure 1.31

Figure 1. Representation of the Fibrinolytic System
In summary, tissue plasminogen activator (t-PA) and urokinase convert plasminogen to
active plasmin. This conversion process initiates fibrinolysis (enzymatic breakdown of
fibrin). Damage caused in the endothelium and surrounding blood vessels releases t-PA to
mitigate clot formation. Clot break down occurs after several days, indicating break down
depends on t-PA accumulation. Due to entrapped plasminogen in clots, activation degrades
the fibrin mesh. Urokinase and t-PA are inhibited by plasminogen activator inhibitor-1/2
(PAI-1, PAI-2), activation is governed by t-PA and urokinase concentrations. Further,
plasmin inactivation is mediated by Alpha 2-antiplamin, alpha 2-macroglobulin, and
6

thrombin-activated fibrinolysis inhibitor.31 The latter induces conformational changes in
fibrin to promote t-PA-mediated plasminogen resistance.2
Microvascular injury causes an influx of blood into the wound space.3 Contractions
within the vascular smooth muscle matrix constrict injured blood vessels. This results in
the stoppage of bleeding; however, efficacy is only defined in blood vessels which are
located transversely to the constricting muscle. The hypoxic and acidic environment
created in-vivo allows continuation for several minutes. Consequently, bleeding resumes
as the wound wall relaxes.32 In order to limit blood loss, clots are formed and platelets
aggregate, which is mediated by the coagulation cascade.32
Platelet cytoplasm constituents include: vasoactive amines and α-granules filled
with growth factor cytokines: platelet derived growth factor (PDGF), transforming growth
factor (β (TGF-β), epidermal growth factor, and insulin like growth factor. These growth
factors are concert molecules, promoting completion of the inflammatory cascade.
Chemo-attractive agents, such as TGF-β, C2a, C5a, and formyl methionyl peptides
initiate activation of the complementary wound healing cascade. This cascade is
responsible for infiltration of the wound site by neutrophils. Neutrophils begin the process
of phagocytosis, acting as a cleaning step for any potentially foreign pathogenic
constituents. Neutrophil attraction occurs 24-36 hours after tissue damage. Once neutrophil
infiltration is complete, alterations in regulatory surface adhesion molecules allow for
neutrophil adhesion to endothelial cells in post-capillary areas.33
7

As blood continues to spill into the wound site, blood components interact with
exposed collagen structures. Due to its high amount of dissolved oxygen, the blood exhibits

Figure 2. Representation of the Common Clotting Pathway
highly corrosive properties.31,34 This interaction triggers the release of fibronectin, fibrin,
vitronectin, and thrombospondin, all clotting factors, as described in Figure 2.34 The overall
impact of the release of these clotting factors leads to the development of a temporary
matrix for cell locomotion. Continued blood flow pushes neutrophils toward the wound
site to initiate phagocytosis. Following wound clean up, neutrophils are eliminated and
extruded to the wound surface by apoptosis. Macrophages begin further clean-up of cell
remnants and apoptotic bodies.
48-72 hours after wounding, macrophages continue phagocytosis. Arrival of
macrophages is indicative of continual pH fluctuations. Figure 335 represents the entire
wound healing process with respect to time, major skin healing events, and cell
8

interventions.

Figure 3. The healing time frame expressed in days (D), weeks (W) and years (Y); ii)
The main cell and tissue events; iii) the quality of the skin; iv) the major cell and cell
subsets involved
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Further, macrophages act as a repository for previously mentioned growth factors
and mediators.36-38 Lymphocyte arrival is mediated through attraction to interleukin-1 (IL1) and immunoglobulin G (IgG) metabolic products. These constituents regulate
collagenase activity, which governs collagen remodeling, cellular matrix component
production, and catabolism.39 This process is summarized in Figure 4.40

Figure 4. Representation of the Inflammatory Phase of Wound Healing
1.3. The Proliferative Phase:
Proliferation is the next step in the wound healing cascade. The proliferation process
is characterized by re-epithelization, vascular network restoration, and granulation tissue
formation. Re-epithelization is mediated by a variety of factors including: migration and
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proliferation of keratinocytes. This process occurs within 48-72 hours of wounding and is
illustrated in Figure 5.40

Figure 5. Representation of the Proliferative Phase of Wound Healing

Wound edge keratinocytes migrate away from the wound. Consequently, keratinocyte
migration initiates recruitment of basal and wound edge level keratinocytes and epithelial
stem cells. These constituents nucleate the proliferation process.40 Proliferation is triggered
by loss of physical tension and cell adhesion to desmosomes and hemi-desmosomes, which
is governed by CD-44, a cell-to-cell adhesion molecule. Membrane associated kinases
increased permeability to calcium. This facilitates reorganization of the cytoskeleton and
increases constituent migration.41
As migration progresses cells are released from their original sites. This process is
mediated through the triggering of collagenase and elastase, resulting in the creation of
new adhesion structures. Once these structures are created, migration is terminated.42
11

Keratinocytes secrete proteins to rebuild the basement membrane, which marks the
beginning of the re-epithelization process.43 This process is initiated by nitric oxide that is
synthesized by macrophages as well as various growth factors (endothelial growth factor,
keratinocyte growth factor, IGF-1, and nerve growth factors).44
Following re-epithelization, neovascularization begins. Initiation of this process is
governed by vascular endothelial growth factor (VEFGF), PDGF, basic fibroblast growth
factor (bFGF), and serine protease thrombin.43-45 In concert, these growth factors activate
endothelial cells of the residual vessels. Culminating in the secretion of proteolytic
enzymes that dissolve the basal lamina. This dissolving process facilitates migration and
proliferation of endothelial cells toward angiogenic stimulus. The impact of angiogenesis
allows for the reformation of vessel lumens, arteries, and venules. Angiogenesis matures
through recruitment of pericytes and smooth muscle cells, which restore functionality to
the wounded area.45
Once granulation tissue forms, the provisional wound matrix formed during
hemostasis is replaced. Granulation tissue is composed of fibroblasts, granulocytes,
macrophages, blood vessels, and collagen bundles. Together, these constituents restore
structure and function to the wounded skin. Fibroblasts contained within granulation tissue
begin to proliferate. This serves a critical role in tissue formation. These fibroblasts migrate
from the dermis in response to growth factors such as: PDGF, TGF-β, and bFGF,
synthesized by platelets and macrophages in the wound.46 In chronic wounds, fibroblasts
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originate from fibrocytes and bone marrow derived mesenchymal progenitor cells.47 They
migrate to regions of skin injury and contribute cytokines, chemokines, as well as
previously discussed growth factors; further, they serve as antigen presenting cells to
enhance angiogenesis.48
Overall, fibroblasts migrate into the provisional cell matrix and produce matrix
metalloproteinase (MMPs) to degrade the provisional matrix. Once the provisional matrix
is degraded, collagen and extracellular matrix components are deposited. These include:
proteoglycans, hyaluronic acid, glycosaminoglycans, and fibronectin. Constituents are
formed from granular tissue and provide a scaffold for cell adhesion, growth, migration,
and differentiation.49-52
1.4. The Maturation Phase
Maturation initiates at the terminal point of granulation tissue development, this
phase of wound healing is illustrated in Figure 6.40 As mentioned before, mechanical

Figure 6. Representation of the Maturation & Remodeling Phase of Wound Healing
tension and cytokines spur fibroblast differentiation into myofibroblasts. These cells
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express α-smooth muscle actin (SMA), which acts to contract the wound.53 Complete
wound healing is characterized by myofibroblast apoptosis, which allows for the
replacement of collagen III with collagen I, in the extracellular matrix. Consequently, the
extracellular matrix exhibits higher tensile strength, a decrease in new blood vessels, and
diminished blood flow. Environmentally, this creates an avascular and acellular condtion.54
In cases of serious injury, hair follicles and sweat glands cannot be fully recovered,
commonly known as scarring; wherein, newly healed skin achieves ~80% of its original
tensile strength.55
1.5. Chronic Wounds:
The aforementioned wound healing processes are exhibited when a wound
undergoes normal wound healing. In chronic wounds, various growth factor equilibriums
can be unbalanced. Consequently, wound fluid fails to stimulate DNA synthesis. DNA
synthesis failure reduces the level of PDGF, bFGF, EGF, and TGF-β.56 Conversely, growth
factors present in would fluid may be trapped in fibrin cuffs surrounding capillaries,
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effectively rendering them inactive. Further, presence of wound proteinases inhibits growth
factor activity.57 Figure 758 shows a representation of this cascade.

Figure 7. Representation of Chronic Wound Development
Development of disruptions in acute wounds facilitates chronic inflammation.
Physiologically, chronic inflammation is characterized by an increased concentration of
inflammatory cytokines, leading to a higher population of neutrophils, macrophages, and
mast cells. These cells, in turn, secrete proteases and reactive oxygen species. Over time,
these constituents are chronically elevated culminating with off-target destruction of
essential proteins for healing. Prolonged destruction of these proteins leads to the
development of a chronic, non-healing wound.59
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Wound healing phase disruptions are characterized by complications with
chemotaxis, hemostasis, neovascularization, and reepithelization.60 These processes are
mediated through a variety of in-vivo signaling pathways, including the endocrine,
autocrine, paracrine, and intracrine pathways. Cellular mediation is carried out by
cytokines utilizing nitric oxide and other cellular elements.61 Process completion is
characterized by cellular recruitment of macrophages and neutrophils, as well as collagen
network development. As the wound heals, it develops a particular pH gradient, where each
phase can be identified. Overall, irregularities in developmental milestones do not allow
for proper wound closure, which increases the likelihood of scarring.61
1.6. Chemical and Physical Biomarkers used in Current Biosensors:
In order to accurately and precisely monitor wound healing progression, flexible
biosensors are utilized to quantify specific biomarkers (e.g. glucose, IL-6, lactate, pH and
oxygen). These biomarkers are integral to discerning wound progression and status. Such
biomarkers provide clinicians continuous data when coupled to a point of care system.
Wound site values for glucose, lactate, pH, oxygen, interleukin-6, temperature, and blood
pressure elucidate healing progression and inflammation status.62 Implicated biomarkers,
along with what they indicate, normal physiological ranges, illness values, and main
mechanism of quantification are summarized in Table 1.63
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In cases of skin injury of the lower extremities, patients with diabetes mellitus are at an
increased risk of amputation, as blood circulation and oxygenation of tissue is
comprimised.71 In wound healing, deficiencies in growth factor production due to high
levels of glucose inhibits growth factor production, angiogenesis, macrophage function,
collagen deposition, keratinocyte and fibroblast aggregation at the wound site, and scar
strength.71 Current methods in measuring glucose levels depend on electrochemical
chronoamperometry.62 Specific analyte levels are targeted on the working electrode to
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generate direct current. Over time, sensing can be tuned to select for enzymatic and nonenzymatic glucose. Sensing enzymatic glucose utilizes immobilized glucose-oxidase on
the surface of the electrode surface, degrading glucose into gluconic acid, illustrated in
Figure 8.72

Interleukin-6 is a pro-inflammatory cytokine in the inflammatory response of
wound healing.73 Sustained, high levels of IL-6 degrade the extracellular matrix, impede
cell migration, and prolong the inflammatory wound healing response.74 In-vivo levels of
Glucose Oxidase

Electrode

Graphene Substrate

Figure 8. Demonstration of immobilized glucose oxidase on the sensing surface.
IL-6 range from 0-2.4 pg/mL and is absent in tissue.75 Uncharacteristic levels of IL-6 in
blood manifest above 2.4 pg/mL and 1.27 ± 1.7 pg/μg in the wound bed. These elevated
levels serve as markers for inflammation and elevated metalloproteinases.75
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Lactate is produced because of oxygen deficiency during anaerobic activity. 62
Normal lactate levels range from 0.5-1.5 mM in blood; however, sustained levels above
1.5 mM indicates hyperlactatemia.66 In healthy tissue, lactate levels are between 1-3 mM,
fibroblast function is inhibited at concentrations above 7 mM at the wound site.76 Further
indications of more serious conditions, occurring outside of normal blood lactate
concentrations, that impair the wound healing process include: lactic acidosis, lactic sepsis,
or tissue hypoxia.66 Current sensing modalities utilize chronoamperometry.
pH is critical in determining physiological status. In chronic wounds, pH fluctuates
between 7.15 and 8.90 in the wound bed. While undergoing tissue repair, wound bed pH
decreases to a more acidic state of 4-7. Effectively, the acidity increases fibroblast activity,
decreases irregular collagen formation, inhibits bacterial viability, and impairs
metalloproteinase enzyme degradation rates.77 Conversely, a more basic pH individuates
atypical healing, with further indications of pathogenic infection, alkalosis, or a chronic
would.78
Oxygen concentration is determined by hemoglobin concentration and partial
pressure of dissolved oxygen in blood.79 In homeostatic conditions, 97% percent of oxygen
is transported through the bloodstream by hemoglobin, while 3% is dissolved in the
blood.69 This results in a range of 50 to 130 μM of oxygen.80 In systemic arterial blood, the
partial pressure of dissolved oxygen typically ranges between 95- 100 mmHg and 0 to 10
mmHg in systemic venous blood.69 Sustained inflammation changes the dissolved oxygen
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levels in wound exudates to a range of 5 to 20 mmHg.81 Uncharacteristic levels of oxygen
can indicate carbon monoxide poisoning, mass cell apoptosis, pH fluctuations, and
facilitate over expression of pro-inflammatory cytokines like (IL-6, IL-1β, and TNF-α).81,
69

1.7 Current Bandages/Adhesives
Current bandages and adhesives function by imparting pressure over the wounded
surface, to facilitate clotting. Their effects are largely mechanical in nature, depending on
location and placement on the patient. Recently, consumer bandages now contain antibiotic
species, most commonly: neomycin sulfate, polymyxin B sulfate, and bacitracin zinc.
Neomycin sulfate, as depicted in Figure 9, is an aminoglycoside antibiotic,

Figure 9. Chemical Structure of Neomycin Sulfate
characterized by the presence of two or more amino sugars coupled by glyosidic bonds. It
is typically used in topical preparation; however, there are approved oral administration
methods, the first use occurred in 1952 after approval.6 Once ingested, neomycin is not
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absorbed in the gastrointestinal tract. Through regulation of intestinal tract bacteria,
ammonia levels are mediated. It is efficacious against streptomycin-resistant bacteria.6
Microbes with antibacterial resistance are leading causes for infection in wounds, thus
leading to the development of chronic wounds. These infections interfere with the normal
wound healing processes, as the immune response is prolonged, thereby delaying the
proliferative and remodeling phases of wound healing.82-84 Its efficacy stems from
inhibition of protein translation in mRNA through binding with the 30S subunit of the
ribosome.85 Further, it exhibits high binding affinity for phospholipid components of cell
membranes, specifically phosphatidylinositol 4,5-bisphophate.86 In DNA binding,
aminoglycosides, have high affinity for duplex RNA.7
Polymyxin B sulfate, discovered in 1947 and shown in Figure 10, is primarily used

Figure 10. Chemical Structure of Polymyxin B Sulfate
for Gram-negative resistant infections, which include Escherichia coli, Pseudomonas
aeruginosa, Neisseria gonorrhea, Chlamydia trachomatis, and Yesinia pestis.87 Their
21

application in wound care is for their ability to bind to cell membranes and induce increased
permeability, leading to increased water uptake and cell death. Chemically, it is a cationic
peptide with basic properties with functionality akin to surfactants. Mechanistically,
polymyxins bind to negatively charged sites in the lipopolysaccharide layer in bacterial
outer membranes, leading to increased permeability.8 Following successful binding,
conformational changes induce fatty acid dissolution in hydrophobic regions of the
cytoplasmic membrane, leading to diminished membrane integrity. After fatty acid
dissolution, cellular molecules leak out, inhibiting cellular respiration, with further
polymyxin binding to endotoxins, leading to deativation.88
Bacitracin zinc, as illustrated in Figure 11, is a cyclical peptide with the capacity to

Figure 11. Chemical Structure of Bacitracin Zinc
disrupt Gram-positive bacteria through cell wall interference and disruption of
peptidoglycan synthesis. This is achieved through interaction with the dephosphorylation
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of C55-isoprenyl pyrophosphate and bactoprenol pyrophosphate. These species are both
lipids with critical cell function. Their functionality is defined as membrane carrier
molecules with critical significance in peptidoglycan synthesis.89
1.8 Zeolite (QuikClot)
Zeolite, as illustrated in Figure 12, is of particular interest in wound healing

Figure 12. Composition of Zeolite surface configuration in the H+ from
applications due to its cation exchange and molecular sieve characteristics. Zeolite is a
crystalline solid composed of aluminum, silicone, and oxygen.12 In pig wound models,
formulations of nitric oxide-zeolite particles, in ointment form, caused a 2.5-log reduction
of viable bacterial colonies (104 CFU/gram of tissue), compared to controlled wound and
treated wound, after six days of treatment. Further, treated wounds healed significantly
faster than control wounds (36% vs 26% per day, p = .03).90
Specifically, in wound healing, topically applied zeolite-based materials aid in the
construction of scaffolds for tissue engineering. In this application, zeolite mimics the
mineral rich component of the natural bone substrate. These composites promote
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proliferation of human fibroblasts and mesenchymal stem cells (MSCs) as well directed
differentiation of MSCs towards osteoblasts.91
Although zeolite material composites feature hard characteristics, zeolite has the
capacity for application in soft-tissue-engineering, specifically in vascular and skin tissue
systems, because of its molecular sieve characteristics. 3-D scaffolds consisting of
polyurethane were embedded with fluorinated zeolite Y crystals. Subsequently, these
scaffolds had a significant impact on the proliferative and penetrative capacities of human
coronary artery smooth muscle cells.13,92 This is because of zeolite acts as a reservoir for
oxygen, enhancing oxygen delivery to the cells.92 Increased availability of oxygen
promotes synthesis of growth factors which facilitates cellular proliferation.93
1.9 Polyethylene Glycol (PEG) Based Wound Sealants
Wound sealants are used to promote reconnection and sealing of tissue after
wounding or surgical procedures.94-95 Current challenges associated with wound closure
include elasticity and adhesion. As an example, cyanoacrylates exhibit desirable stiffness
and adhesion; however, is cyto-toxic, and is not elastic.96 PEG, illustrated in Figure 13,
materials are now being utilized for

Figure 13. Chemical Structure of Polyethylene Glycol (PEG)
24

wound sealants, as they are nontoxic and inert.97 In in-vitro studies, utilizing L929 cells
(mouse line) PEG hydrogels treated cells exhibited long spindled shapes, with lamellipodia
and fiopodia. These visual characteristics were evidence against cytotoxicity, as the cells
were not presenting lysed characteristics (rounded shape).98 Quantitative viability
assessments yielded 81% viability for test samples utilizing PEG hydrogels. When
compared to high density polyethylene for negative control, 10% dimethyl sulfoxide for
positive control, and culture medium for blank, of 99%, 28%, and 100% respectively. Table
2 summarizes these results.98
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1.10 Hyaluronic Acid Based Hydrogels:
Hyaluronic acid (HA), illustrated in Figure 14, is a type of polysaccharide of the

Figure 14. Chemical Structure of Hyaluronic Acid
glycosaminoglycan class, it consists of two sugar base units: glucuronic acid and N-acetylglucosamine.99 In biological systems, HA is found in synovial fluid, surrounding joints and
cartilage, as well as eye and dermal tissue. Recent studies have implicated HA as treatment
agent for accelerating wound healing, increasing cellular proliferation, and improving skin
graft quality. These studies are tabulated in Table 3.100
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1.11 Chondroitin Sulfate (CS):
While commercial bandages and topical ointments have been heavily utilized and
are the state-of-the-art, there has been a growing interest in using natural/biopolymers for
applications in biomaterial development, along with tissue engineering and wound healing.
Glycosaminoglycans (GAGs) are a family of naturally occurring biopolymers that are
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ubiquitous in the extracellular matrix (ECM). GAG functionality is derived from their
negatively charged polysaccharides. These anion sites present efficacious characteristics

Figure 15. Chemical Structure Denoting Sulfonation Differences in Chondroitin Sulfate
A, C, D, E, H, and K
such as: ECM and bind effector molecule hydration capability.9,107-108 CS, specifically,
consists of a repeating network of sulfated disaccharide, which contain Nacetylgalactosamine. CS chains are classified by type: A, C, D, E, H and K.10 They are
named CS A (C-4-S), C (C-6-S), D (C-2,6-S), E (C-4,6-S), K (C-3,4-S) and H (IdoAa1–
3GalNAc(4S,6S)), illustrated in Figure 15. C-4-S and C-6-S are the most ubiquitous.
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During the proliferative phase of wound healing, CS is released. This phenomenon
implicates CS as an integral constituent in the wound healing process. In wound healing,
injection of glycylhistidyl-lysine-Cu2+, a wound healing activator, into rat wound models,
results in accumulation of CS, resulting in stimulation of wound tissue production, as
shown in Figure 16 and demonstrated in 2000 by Simeon.11

Figure 16. Injection of GHK-Cu Increases Accumulation of GAG in the Wound
Chamber, as Measured by Total Uronic Acid
Content Reprinted with permission from “Expression of glycosaminoglycans and small
proteoglycans in wounds: modulation by the tripeptide-copper complex glycl-L-histidylL-lysine-Cu(2+)” by Alain Siméon, 2000, J. Invest. Dermatol. 962-8. 2000 by Elsevier.
In nasal mucosa, at the 4-day endpoint, CS hydrogels have been found to accelerate
wound healing.109 Of particular significance is understanding CS’s efficacy in regulation
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of cellular adhesion, proliferation, cell cycle, and performance in in-vitro 2-D and 3-D
wound closures, and contraction rate.
In fibroblast adhesion, CS impact was demonstrated through culture of fibroblasts
in the presence of chondroitinase ABC (an enzyme that breaks down CS). After culture,
degradation of exogenous CS reduced the number of adherent cells significantly. This
suggests that CS is necessary for cell adhesion. Conversely, fibroblasts cultured in medium
supplemented with exogenous CS exhibited increased cell adhesion.110 This phenomenon
is demonstrated graphically in Figure 17.110
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Figure 17. Regulation of fibroblast adhesion by CS. Degradation of Cs by the addition of
Chondroitinase ABC to the culture medium for 8hrs lead to a decrease in the number of adherent
cells. Addition of exogenous CS (C-6-S) led to an increase in cell adhesion
CS regulated fibroblast proliferation has been documented and assessed through
cytometry of metabolically active cells after days of culture. In cultures where endogenous
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degradation of CS was the treatment, the number of proliferating cells was significantly
reduced. This result suggests that CS is integral to successful cell proliferation. In
fibroblasts, cultured in the presence of CS, cell proliferation increased, illustrating the
importance of CS to cellular proliferation.11,109-110
In order to elucidate the effect of extraneous CS in the 2-D wound healing model,
the effect of the absence of CS was first analyzed. In this model, the effect of chondroitinase
ABC on wound closure was assessed, where the measurement parameter was wound
closure. After investigation, wound distance, in the presence of chondroitinase ABC,
decreased 75.3% in 18hrs after wounding, compared to 92.6% reduction in the 2-D wound
model, without extraneous CS or chondroitinase ABC. In the presence of extraneous CS
(1000 ng/ml), wound closure was significantly accelerated (p < .05). In the 3-D wound
healing model, fibroblast gel contraction was observed within 24 hours after cell seeding.
With significant contraction becoming apparent within 72 hours. Extraneous C-6-S
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inhibited cell-gel contraction, 72 hours after gelling, yielding only 6% contraction, depicted
in Figure 18.110

Figure 18. The association of CS in wound contraction. (A) Cell-gel had more than 50% contraction
after 72hrs. (B) Addition of C-4-S had no significant effect. (C) Addition of C-6-S led to almost no
contraction. (D) Comparison in the difference of contraction rates
Reprinted with permission from “Specific interactions between human fibroblasts and particular
chondroitin sulfate molecules for wound healing” by XH Zou, 2009, Acta biomaterialia, 5(5), 15881595. 2009 by Elsevier.
Cell adhesion is integral to successful wound healing.111 The affect that CS had on
fibroblast adhesion may be attributed to integrin medial cell adhesion. This results in
localization of focal adhesion kinase (FAK), a cytoplasmic protein tyrosine kinase.
Localization of FAK is concentrated at focal adhesion points, as well as tyrosine
phosphorylation of FAK.112-112 α4β1 integrin has been reported a binding site for CS.114 In
order to enhance FAK phosphorylation, CS is needed for α4β1 integrin-mediated cell
adhesion.115 Further, the ability for CS to bind to fibroblast growth factor-2 (FGF-2) may
assist FGF-2 induced cell proliferation.116-117 The FGF consists of 22 derivative growth
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factors, with the capacity to stimulate proliferation of gingival fibroblasts. In rabbit models,
topical application of FGF-2 resulted in accelerated healing of gingival ulcers.118-119
In the 2-D wound healing model, the function of extraneous CS promotes cellular
migration and dispersion. CS proteoglycan facilitates cellular dispersion and migration
through activation of FAK and inhibition of RhoA activity.115 Facilitation of cellular
dispersion and migration, by FAK, down-regulates RhoA activity. RhoA is a member of
the GTPase family, wherein its activation forms focal adhesions and stress fibers,
illustrating how high levels of RhoA inhibits cellular migration.120 Figure 19121 illustrates

Figure 19. Signaling pathways of FAK and Src, controlling actin cytoskeletal rearrangement, and
FAs. Integrin β1 can be activated by reelin and induces recruitment and stimulation of FAK and
Src, which control cell migration and adhesion via regulation of the actin cytoskeleton and FA
complex.
Reprinted with permission from “Abnormal cell properties and down-regulated FAK-Src complex
signaling in B lymphoblasts of Autistic subjects” by Hongen Wei, 2011American J. of Pathology,
179(1), 66-74. 2011 by Elsevier.
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the interaction between the signaling pathway of FAK and Src kinase controlling
cytoskeleton rearrangement and ultimately impacting cellular migration and adhesion.
Regarding the function of CS in the 3-D wound healing model, 3-D matrices
composed of type I collagen have been utilized historically. 3-D models are more
congruent with natural physiological processes associated with wound healing, than 2-D
models.122-123 In the 3-D model, CS was able to efficiently mediate the contraction process
of collagen by human fibroblasts through inhibition. Together, this suggests that CS, as a
treatment, is able to abate contractile behavior of fibroblasts. The overall impact, although
specific mechanisms have not been described in the literature, is correction of
uncharacteristic fibroblast activation, with therapeutic applications.110
1.12 Engineering Biosensor Devices Utilizing Graphene-Based Materials
In the past, different synthetic methods yielding efficacious structural and material
properties were utilized for the development of biosensing application. This is due to
graphene being a semi-metal with ultra-high charge mobility, large surface area, and the
capability for surface functionalization.17 Many different methods exist to engineer the
biomolecular receptor for biosensing. In the biomedical field, pristine graphene is referred
to as an oxide-free graphene, presenting with π-π stacking, non-covalent interactions, and
high electrostatic force. Further, it allows for an infinite sensing surface at the molecular
level. Thus, graphene has a high probability of presenting active sites for chargebiomolecular interactions. This large surface area also leads to enhancements in sensing
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capability as well as the supporting desired functionalization to the target biomolecule of
interest. Figure 2017 illustrates differing interactions of graphene-based systems. As an

Figure 20. Illustration of graphene-based sensors that can be immobilized with biomolecules at the
receptor surface.
example, the areas of pure graphene as shown in the figure can provide a charged space to
interact any molecules of interest or metal ions, with further interactions at the vacancy
defect. Functionalized graphene areas are able to directly detect biomolecules by intrinsic
oxide components due its synthetic process where a great deal of epoxide, hydroxyl, and
carboxyl groups are formed and accumulate on the edges and surface sites. Additionally,
functionalized graphene allows for binding of heteroatoms, nanoparticles (NPS), quantum
dots (QDs), DNA enzymes, proteins, antibodies, and antigens.124-126
In biomedical use cases, nanostructures based of graphene have been recently
reported to have highly selective and sensitive characteristics as biosensors, for biomarkers
associated with wound healing, as tabulated in Table 4.17
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Table 4: Current graphene-based biosensors and their biomolecular targets
Technique
Receptor System
Target
Limit of
Reference
Biomolecules
Detection
GFET
Graphene
DNA
10 pM
127
GpO FET
GpO/Cu or AgNPS
Glucose
1 µM
128
RGO FET
Urease/PEI/RGO
Urea
1 µM
129
GLSPR
Ni/graphene
3-NT
0.13 pg/mL
130
SPR
RGO
Rabbit IgG
0.3125
131
µg/L
SPR
Graphene-MoS2
ssDNA
132
ECHEM
Go-ssDNA/Au
VEGF
0.05 ng/mL
133
ECHEM
Anti-human D-dimer
D-dimer
1 µM
134
antibody/lipid film/
graphene nanosheets
Electron
MoS2/GO
Glucose in
65 nM
135
transfer
human serum

1.12.1 Engineering Biomolecule Based Biosensors using Pristine Graphene
With graphene-based biosensors, graphene improves the sensitivity, limit of
detection (LOD), and the overall performance of the biosensor. This is done by enhancing
the charge or electron transfer between the graphene and biomolecule of interest. As an
example, for a label-free and portable aptasensor scheme, pristine graphene is utilized for
the electrode in a field effect transistor.136 The biosensor detects Pb2+ ions in children’s
blood. There are varied components in blood, as it is composed of Na+, K+, Mg2+, and Ca2+,
at levels lower than 0.1 M/L. This limit, is approximately one thousandth of the safety limit
(100 µg/L) for Pb2+ in blood.17
A novel, paper-based biosensor, utilizing the efficacious electrochemical
properties of graphene, was developed for human papillomavirus (HPV). 137 The sensing
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electrode was modified using a labeled peptide and printed utilizing the inkjet printing
method. The surface chemistry involved using a negatively charged amino acid on the
graphene electrode, by way of electrostatic attraction. The target amino acid was a synthetic
14 base oligonucleotide with a sequence corresponding to HPV type 16 DNA. The
electrochemical response to the label was measured and was able to identify primary stages
of cervical cancer.
Integrated graphene microelectrodes with lipid bilayer membranes have
resulted in efficacious findings, in both static and stirred experiments.138 Further, due to
the structural properties of the membrane, the developed sensor was reusable, had high
sensitivity, and the results were reproducible.

These characteristics, taken together,

enabled direct potentiometric measurements.138
1.13 Mechanism of Injury (Combat/Civilian/Austere)
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Table 5 presents first, second, and third generation hemostatic products approves
by the CoTCCC for battlefield use. Military and civilian mechanisms of injury have been
traditionally different. However, given the rise of terrorist attacks utilizing improvised
explosive devices (IED), more than 53,000 civilians and military personnel were killed or
injured between 2011 and 2013 globally.20 Trauma originating from penetrating
fragmentation used by explosive devices is now becoming more common in developed
countries, as evidenced by the Boston Marathon Bombing in 2014, Paris is 2015, and
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elsewhere.139 The best practices from battlefield lessons learned for hemorrhage control
should be applied universally, regardless of casualty type or location.20
For nearly the last two decades of combat casualty care in Afghanistan and Iraq,
the main mechanism of injury has been penetration, in approximately 75% of casualties.
The majority of injuries were primarily caused by fragmentation of IEDs (74%). While
more traditional wounds such as gunshot wounds and blunt force trauma comprise 22%
and 4%, respectively.21 A majority of combat deaths occur before the patient reaches a
surgical team. In the military, the leading cause of mortality is: hemorrhage (91%) derived
from three key anatomical regions: truncal (67%), junctional (19%), and extremity
(13%).22,23
The civilian sector’s primary mechanism of injury that leads to morbidity and
mortality is blunt force trauma (79-89%) and penetrating trauma (11-22%). Of the
immediate to early deaths, the proportion (50-60%) from either cause is constant, with
death being the primary result of traumatic brain injury or hemorrhage. These findings have
been constant over many decades.24-25,139-140 In austere settings, traumatic brain injury or
trauma effecting multiple body systems is the leading cause of morbidity or mortality,
where victims fall from height.141-145
1.13 Effectiveness and Evolution of Hemostatic Agents/Dressings
Historical use of hemostatic agents and dressings for mitigating bleeding, by the
Department of Defense, is presented by multiple authors.29,146-148 In summary, the first
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1996 TCCC Guidelines did not have US Food and Drug Administration (FDA)-approved
hemostatic agents useable for battlefield care.147 Ensuing research into hemostatic agents
endeavored to develop an efficacious product to mitigate major bleeding within minutes of
wounding, that was both safe for the patient and the medic; easy to use for stakeholders,
easy to transport and rugged, has a long shelf life, and cheap.149 During the 2003 TCCC
guideline revision, several products were efficacious in controlling bleeding in animal
models.150-154
The primary agents that were selected for battlefield casualties were the chitosanbased bandage HemCon (HemCon Medical Technologies, Portland, OR) and the zeolitebased powder QuikClot (Z-Medica, Wallingford, CT). Efficacy was equal in both products
for controlling severe bleeding, based on pre-clinical studies; however, no product was
more advantageous at the time.20 Of note, military surgical teams reported first, second,
and third-degree burns were observed in surrounding tissue after QuikClot application.
These burns were explained by the exothermic reaction that occurs when blood makes
contact with the zeolite granules after application in soft tissue wounds.155 Because of these
adverse effects, the Committee on Tactical Combat Casualty Care (CoTCCC) designated
HemCon bandages as the preferred initial hemostatic agent.26
The CoTCCC undertook a literature review on hemostatic dressings for application
in tactical medicine guideline revisions.20 This review consisted of input from combatexperienced first responders and trauma surgeons in order to juxtapose their experience
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with QuikClot and HemCon. Additionally, a review of the literature was conducted to
elucidate new information utilizing animal models for efficacy. Overall, however, the
CoTCCC did not select an obvious winner for efficacy based off of laboratory studies or
case reports in practice.20 In 2006, the TCCC guidelines were revised, resulting in both
HemCon bandages and QuikClot granules being recommended to be carried on the
battlefield. However, QuikClot was designated as the secondary agent of choice to
HemCon.149,156
Following the 2006 TCCC revision, published in the Prehospital Trauma Life
Support Manual, new hemostatic agents/dressings were evaluated by the United States
Army Institute of Surgical Research and the Navy Medical Research Center found that two
new materials, QuikClot Combat Gauze (Z-Medica) and WoundStat (TraumaCure,
Bethesda, MD) were more effective on a consistent basis, than the previously reported
agents (QuikClot and HemCon)157,158. As a result, the CoTCCC voted to recommend
QuikClot Combat Gauze as the primary treatment for critical hemorrhage that is not suited
for placement of tourniquets, with WoundStat designated as the secondary agent.29 The
reasoning used for this prioritization was based on the experience of medics and corpsmen
preferring gauze type hemostatic agents, as powdered or granulated agents were less
effective in wounds where the bleeding vessel is located in a narrow wound tract or in
windy battlefield conditions.147 However, due to subsequent animal testing, WoundStat, a
granular material, was removed from the TCCC guidelines as a secondary to QuikClot
Combat Gauze due to thrombotic, embolic, and tissue complications.159
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Between 2008 and 2014, no formal reviews were conducted for new hemostatic
agents/dressings. New, consistent data derived from animal models for severe hemorrhage
show chitosan-based hemostatic gauze dressings for battlefield applications are as effective
as QuikClot Combat Gauze. A total of eight studies reported equivalence and efficacy of
chitosan-based dressings with QuikClot Combat Gauze in preclinical models of extremity
arterial hemorrhage.29,

160-167

Additional studies reported successful outcomes utilizing

updated chitosan-based dressings (Celox Gauze, MedTrade Products Ltd, Crew, UK) in
the civilian sector, based on hospital case reports168-170 and prehospital battlefield case
reports.171-172 Additionally, no safety concerns or complications have been reported in these
cases, across the years of chitosan-based hemostatic dressing use (HemCon and Celox) in
applications for the military173-174 or in civilian sectors.175 Utilizing the evidence based
literature review, the CoTCCC chose to add ChitoGauze Pro and Celox Gauze (HemCon
Medical Technologies, Portland OR) into the TCCC Guidelines as well as QuikClot
Combat Gauze.29 Since 2008, QuikClot Combat Gauze has remained as the primary
hemostatic dressing due to its utility and effectiveness.20
In 2015, a new FDA approved hemostatic product called XStat (RevMedx,
Wilsonville, OR) was incorporated into the CoTCCC guidelines.176 Effectiveness was
based on product utility and preclinical animal wound models.163,177-178 The need for the
XStat exists in deep-tract or narrow-entrance wounds, aiding in hemorrhage control. Its
efficacy is defined through its use of a syringe delivered, expandable, nonabsorbable,
hemostatic sponge. These sponges are designed for temporary use for junctional, non42

compressible wounds, i.e. wounds were tourniquets are not applicable. Once the sponges
make contact with blood, they expand – filling the wound cavity, providing pressure as
well as a physical barrier in the wound to aid clot formation. Overall, the device is for
temporary use, up to 4 hours until surgical care can be rendered. XStat cannot be used in
in the abdomen, thorax, the retroperitoneal space, sacral space, tissues above the clavicle,
or above the inguinal ligament. XStat was designed for use in the battlefield or civilian
tactical medical environments, and austere environments for low and high velocity gunshot
wounds.20
The first XStat study163 tested efficacy utilizing porcine models with subclavian
and artery and vein bleeding, developed through a 4.5 cm wound. This model was utilized
as subclavian wounds are more difficult to compress when compared to junctional areas
that allow for efficacious pressure distribution during hemostatic gauze application. In the
XStat study group, there were 8 animals as well as 8 in the control group utilizing QuikClot
Combat Gauze. XStat was applied within 4 minutes of wounding. In the control group, one
animal was treated with Kerlix gauze and another was treated with QuikClot Combat
Cause. For this group, the dressings were applied with 3 minutes of direct pressure,
according to the directions supplied by the manufacturer. During the 60-minute time point
(the golden hour) survival was 100% (8/8) in the XStat group and 37.5% (3/8) in the
QuikClot Combat Gauze group.163
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A study undertaken by the Naval Medical Research Unit, San Antonio juxtaposed
QuikClot Combat Gauze with XStat, utilizing a large animal model with subclavian
bleeding. The study reported XStat could be applied in less time than QuikClot Combat
Gauze (31 seconds verses 65 seconds), resulting in less blood loss during time of
application. In the XStat study, survivability of the subclavian vascular injury was
100%. This wound pattern is critical as it is highly lethal in trauma patients.177
2. Experimental
2.1 Materials
Chondroitin sulfate (CS) sodium salt was purchased from Santa Cruz Biotechnology.
Methacrylic anhydride (MAA, 94%, contains 2000 ppm toponal A as inhibitor),
polyethylene glycol diacrylate (PEGDA, Mn = 700 Da), 3-(trimethoxy silyl) propyl
methacrylate (TMSPM, 98%), and (3-aminopropyl) triethoxysilane (APTES, 99%) were
purchased from Sigma Aldrich. Sodium hydroxide pellets (97%, ACS reagent) was
purchased from Acros Organics. Lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate
(LAP, >98%) was purchased from TCI chemicals. 2-propanol (ACS plus), tetrahydrofuran
(THF, anhydrous) and acetone (Certified ACS) were purchased from Thermo Fisher. 200
proof ethanol, anhydrous, was purchased from Decon labs. pH buffers 4-10 were purchased
from Inorganic Ventures. All chemicals were used without further purification. Purified DI
water (18.2 MΩ resistance) used for synthesis and hydrogel formulation was obtained
using Milli-Q IQ 7000 DI water system. 6 well, nunclon delta plates were purchased from
Thermo Fisher Scientific. Growth media consisting of: high glucose Dulbecco’s modified
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eagle medium, 10% fetal bovine serum, and 1% penicillin-streptomycin (PenStrep) were
purchased from Thermofisher Scientific. Trypsin-EDTA (.25%) were purchased from
Thermofisher Scientific. Human keratinocyte (HaCaT) cells were graciously provided by
Dr. Jeffery Travers, of Wright State Physicians.
2.2 Chondroitin sulfate-methacrylate (CS-MA) synthesis
Wang et al.179 synthetic procedure was modified for the synthesis of CS-MA. An
example procedure is as follows: 3 g chondroitin sulfate sodium salt was added to a 3necked RBF, equipped with nitrogen inlet and an additional funnel, and dissolved in 150
mL DI water at room temperature. 57 g of methacrylic anhydride (MAA, 0.370 mol) was
rapidly added dropwise through the addition funnel to the solution with vigorous stirring.
Upon complete addition of MAA, 5 N NaOH solution was added to the mixture until the
pH = 8. NaOH was added as necessary to maintain basic pH for 2 h at room temperature.
After stirring for 2 h, the RBF was sealed and stored in the fridge for 12 h without stirring.
The CS-MA was precipitated in excess IPA (3:1 IPA:reaction volume) and stirred for 1 h.
The solid was allowed to settle for at least 1 h without agitation and then the excess IPA
was decanted. The residual CS-MA gel-like solid that remained was dissolved in the least
amount of DI water possible and precipitated in IPA. The polymer fibers that formed were
stirred in IPA for 1 h followed by a subsequent stirring in 200 proof ethanol for 12 h to
remove any unreacted MAA. The polymer was collected and dried at 80 °C in vacuo. 50%
yield.
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2.3 Chondroitin sulfate-methacrylate polyethylene glycol (CS-MA-PEG) hydrogel
synthesis

Hydrogels were synthesized using the procedure as follows: 1 g CS-MA was
dissolved in 5 mL DI water. 1 g of PEGDA was added to the solution and stirred. 12.5 mg
of LAP (0.042 mmol) was added to the solution and dissolved. The hydrogel solution was
slowly pipetted into a Teflon mold with 4 wells (1 cm x 1 cm x 0.5 cm) which was placed
on a level metal plate. The solution was exposed to 366 nm UV light (Model UVL-56,
Blak-ray lamp, 115 volts, 60 Hz, 0.16 amps) for at least 30 min. The crosslinked hydrogels
were removed and stored in DI water.

2.4 Characterization
Proton nuclear magnetic resonance (1H NMR) spectroscopy was performed on a Bruker
operating at 400 mHz. 1H NMR spectra were obtained from 4.3% (w/v) 0.7 mL solutions
in d-H2O using 64 scans. FT-IR measurements were taken using a Bruker Alpha-R module.
Thermal analysis was conducted using a TA instruments Thermogravimetric Analyzer
(TGA) Q500. The TGA was equipped with an autosampler and nitrogen and air purge
inlets. Cell cycle effects were gauged utilizing a BD Accuri C6 Plus flow cytometer. The
flow cytometer was equipped with an autosampler, and volume intake was limited to 1 mL.
Electrical resistance measurements of graphene field effect transistors (GFETs) and
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devices were conducted using a Cascade Microtech GmbH (type: MPS150-B1A) multiprobe platform with a Keithley interactive test environment interface.
2.5 Graphene Growth
A tube furnace (OTF-1200x-STM, MTI Corp., CA) equipped with a scroll vacuum
pump was used for chemical vapor deposition (CVD) of graphene.180 A 5x1 inch2 copper
(Cu) foil was placed in the furnace and was heated up to 1000 oC at a pressure of 125 mTorr
maintained with a fixed flow of hydrogen. The hydrogen-only reduction step continued for
30 min at 1000°C, which was followed with a flow of methane at a pressure of 1.25 Torr
for 30 min at 1000°C. The furnace was cooled down to room temperature while keeping
the flow of methane and hydrogen. After completion of the growth, graphene was observed
on both sides of the Cu foil. The Cu foil was cut into 0.5 cm x 0.5 cm pieces for transferring
to silicon substrates.
2.6 GFET Chip Preparation
A silicon wafer having 285 nm thermal oxide was diced into ~ 1.8 cm x 1.4 cm
(width x length) pieces, which are used as substrates. After cleaning a silicon substrate
using acetone and isopropanol, source/drain electrodes for the GFET were made using
photo-lithography, e-beam evaporation and lift-off. The process involved sequential use
of double-layer photo-resist (LOR10A/AZ 5214), ~ min of UV exposure, AZ 300 MIF
developer, 4 min O2 plasma cleaning of LOR10A at 200 W RF power, e-beam
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evaporation of 1 nm Ti and 40 nm Au, tape lift-off, 1 min acetone spray and finally
soaking in Microposit Remover 1165 for 5 min at 95 oC.
2.7 Graphene Transfer
Transfer of graphene onto a silicon substrate was done using PMMA as the support
layer. By protecting one side of the Cu foil containing graphene with aluminum foil,
graphene from the unprotected side was removed using reaction ion etching (RIE) for 5
min at 50 W RF power and using 200 mTorr O2. Graphene on the other side of the Cu
foil was then cleaned using acetone and IPA and then coated with a single drop (~ 50 µl)
of 950K PMMA (purchased from MicroChem; diluted to 1% w/v in anisole). The solvent
was removed by heating to 70 °C for ~30 min. The PMMA-coated graphene on Cu-foil
was then exposed to ~ 254 nm UV (Novascan PSD-UV) for 30 min in ambient air. (This
step reduces PMMA residue from the graphene surface at the end of the transfer
process.181) PMMA-coated graphene/Cu piece was then placed in Fe(NO3)3 solution (5%
w/v in deionized water) for ~ 6 hrs to etch Cu; the process leaves graphene supported by
PMMA on Fe(NO3)3 solution. The Fe(NO3)3 solution was later replaced with DI water; a
few drops of isopropanol were added to water such that IPA:water ratio is 1:6. (Use of
IPA in water helps the adhesion of PMMA-coated graphene to silicon surface.182)
Subsequently, PMMA-coated graphene was lifted from the IPA/water mixture and placed
onto a silicon substrate containing pre-patterned Ti/Au electrodes. The substrate was
cleaned using Nano-Strip (purchased from VWR) before scooping the PMMA-coated
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graphene from the IPA/water mixture. The substrate was annealed at 70 °C in air for 20
mins to adhere PMMA-coated graphene to the substrate. The sample was stored at room
temperature PMMA for 3-4 hrs to dry the residual solvents. An ~ 50 µl of acetone was
dropped on PMMA-coated silicon substrate and later dried off. The acetone drop/dry
process was repeated three times to uniformly adhere graphene to the silicon surface.
PMMA was then removed by placing the silicon substrates vertically in acetone at ~45oC
for 30 mins.
2.8 GFET Definition
Graphene was then patterned within the channel (length ~ 10 µm, width ~ 16 µm) area
of GFET using photolithography and O2 plasma etching.
2.9 GFET Surface Modification and Coating with Hydrogel
Graphene FETs were rinsed with acetone and IPA to remove any debris on the chip
surface. The chips were submerged in an APTES or TMSPM solution (5 v:v% in THF) for
10 min. The chips were immediately rinsed with acetone and placed on a level metal plate.
5 µL of the CS-MA-PEG solution was added to the center of the chip and cured for at least
10 min (as described in 2.3). The hydrogel devices were used for testing immediately.
2.10 GFET Device Testing
The pH sensitivity of the GFET device was tested with and without the hydrogel
coating. A typical procedure is described. A GFET chip is placed on to the stage and a 249

point probe measurement was set up (ground: 0 V, 0.105 A compliance). An initial voltage
sweep (10 µA, 10 V compliance, 10 data points) was collected three times to get a
resistance measurement (from I-V curve) for the device. 0.5-1 µL of pH buffer 4-10 (added
sequentially) was to the center of the device and resistance measurements were collected.
The voltage sweeps were conducted every 30 sec for at least 2 min or until the resistance
measurements stabilized. In between each buffer, DI water was used to wash the device
and the water was removed and the device was air dried for at least 30 sec (only for devices
without hydrogel coating, resistance measurements were collected prior to adding more
buffer).
2.11 Human Keratinocyte (HaCaT) Cell Culture
HaCaTs were cultured following a previously reported method.11 HaCaTs were seeded
(4x104 cell/mL) in Nunc (ThermoFisher Scientific) cell-culture treated dishes. They were
allowed to culture for 6 days, until 80-90% confluent. Media was changed every other day.
After visual inspection, plates were placed into the culture hood, with laminar flow and
UV light sterilization. Culture media was aspirated and fresh media was added into each
well. Culture was conducted with media levels at 5 mL per well plate, with media being
changed every other day. After confluency was achieved, determined through optical
microscopy, CS-MA-PEG hydrogels were added to probe cell cycle effects. Effects were
probed on day 1, 3, and 5, probing terminated on day 5.
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2.12 Flow Cytometry of Treated & Untreated HaCaT Cells
Cells were prepared following a protocol provided by BD. In summary: cells were
trypsinized for 10 minutes. After addition of trypsin, cells were relocated to the incubator
for 10 minutes. Following this, trypsin was inactivated through addition of an equal volume
of cell growth media. After inactivation, cells were pelleted through centrifugation for 2
minutes at 1500 RPM at 4°C. the supernatant was aspirated and the pellet was washed with
1 mL of phosphate buffered saline (PBS) and pelleted again. After pelleting, the
supernatant was aspirated and 200 µl PBS 1 mL of ice cold 100% ethanol was added, with
gentle vortexing. the sample was stored in a -20°C freezer overnight. the cells were spun
at 1500 RPM for 2 minutes in a centrifuge, and resuspended in in 500 µl of PBS.
3. Results & Discussion
3.1 Chondroitin Sulfate-Methacrylate (CS-MA) Synthesis
A series of CS-MA hydrogels were synthesized using slightly modified procedures
reported by Wang et al.179 The synthetic scheme is shown in Figure 21.
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Figure 21. Synthetic route for CS-MA
We obtained similar results as described, with increasing amounts of excess MAA added
to the reaction, an increasing degree of substation could be obtained. This was confirmed
by FT-IR, shown in Figure 22. The FT-IR illustrates an increasing peak intensity around
1713 cm-1, corresponding to the ester carbonyl bond stretching of the methacrylate. The 1H
NMR data also showed the methacrylate was successfully substituted onto the CS
backbone (Figure 23b). The neat CS 1H NMR spectrum is provided for comparison (Figure
23a). The 1H NMR was used to calculate the degree of substation by averaging the
integration of the protons corresponding to the alkene of the methacrylate group. We used
the methyl group of the CS amide as a reference (~1.91 ppm). The reference was
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“validated” (to compare to other samples and the neat CS) if the peak around 3.26 ppm
integrated to around 1. This peak corresponds to the amide proton and remained constant
regardless of the degree of substitution. The maximum degree of substation using this
method is 300%, because CS has 3 hydroxyl groups that could be substituted. The highest
degree of substation we were able to obtain was ~67% (less than 1 hydroxyl group
substituted per repeat unit). This is likely due to the competing side reactions that could
occur during the synthesis. The hydroxyl functional groups on the CS compete against
water as a nucleophile. A large excess of MAA was necessary because the anhydride would
likely be hydrolyzed in the NaOH (in water) reaction solution. In addition, steric hindrance
of the large CS backbone could also impact the degree of substitution due to slower reaction
kinetics.

Figure 22. FT-IR spectra illustrating ester carbonyl stretching due to
methacrylate substitution

53

a.

b.

Figure 23. 1H NMR spectra of a) neat CS and b) CS-MA in D2O

3.2 Chondroitin sulfate-methacrylate-polyethylene glycol (CS-MA-PEG) hydrogel
synthesis
The CS-MA-PEG hydrogels were synthesized via radical polymerization using a
UV-active photo-initiator, lithium phenyl(2,4,6-trimethylbenzoyl) phosphinate (LAP).
LAP was chosen as the photo-initiator because of its good water solubility and

54

cytocompatibility compared to Irgacure 2959, which is another common photo-initiator.
The synthetic route and proposed crosslinked hydrogel structure are shown in Figure 24.

Figure 24. Synthetic route for CS-MA-PEG hydrogel
The PEGDA used has a nominal Mn = 700 Da, which is roughly 13 PEO repeat units. We
attempted to make a hydrogel with a lower molecular weight PEGDA crosslinker,
however, due to poor water solubility, the resulting hydrogel was opaque and brittle. The
700 Da PEG based hydrogels had good mechanic properties (qualitatively) and produced
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transparent hydrogels. A systematic study was conducted to optimize the hydrogel
formulation, where cure time and monomer ratio (CS-MA:PEGDA w:w) were varied. The
most robust hydrogel was formulated using a 1:1 CS-MA:PEGDA w:w and cured for at
least 30 min. When the cure time was less than 30 min, incomplete curing occurred, which
was indicated by cracking and embrittlement once the hydrogel was submerged in H 2O.
Additionally, when the monomer ratio was altered, the resulting hydrogels exhibited
undesired properties. When a higher weight ratio of CS-MA in relation to PEGDA, the
resulting hydrogel had very little compressibility and fractured easily when hydrated (when
compressed in hand). A similar result occurred when there was a larger amount of PEGDA
used. When the weight ratios were equal, the resulting hydrogel was ductile and more
compressible in the hydrated and non-hydrated state in comparison.
3.3 Graphene Field Effect Transistor (GFET) device and pH testing
Our objective with this experiment was to illustrate that our hydrogels could be
combined with GFETs to monitor the pH of a wound. The concept was if the hydrogel
could absorb the wound fluid (and facilitate wound healing), the pH sensitivity of graphene
could be utilized to continuously monitor the pH of the wound in conjunction with the
hydrogel coating.
The GFETs each contained 10 devices, however, for the device testing, only 1 was
tested at a time. An image of the device without any hydrogel coating is shown in Figure
25a.
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a.

b.

Figure 25. a) GFET device without hydrogel coating
b) GFET device with CS-MA-PEG hydrogel coating
There have been several studies reported on graphene-based devices for pH sensing. For
comparison, we tested the pH sensitivity of our graphene devices with and without a water
wash in between each addition of a new pH buffer (Figures 26a and b).
a.

b.

Figure 26. Blank GFET devices average change in resistance as a function of pH
a. with a water wash in between bufers b. no water wash in between buffers
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The charts illustrate that there is an overall increase in resistance with increasing pH. This
trend in opposite of what was reported by Lei et al183 with their simple graphene-based
sensor. However, this trend was consistent with all of the devices that we tested, so the
response was validated. The water wash was used to remove any residual buffer that we
believed could have remained on the surface of the graphene after each test. It was assumed
that if residual buffer evaporated on the graphene surface, the resistance would increase
until enough salt collected on the graphene surface, destroying the device. From the figures,
it is clear that the resistance increased exponentially in both experiments. However, the
resistance increased sooner without the water wash between buffers, as expected.
The devices were coated with the CS-MA-PEG hydrogel and Figure 25b illustrates
a typical device. A silane surface modification was necessary in order to improve the
interfacial adhesion between the hydrophilic hydrogel and the hydrophobic graphene
surface. Two silane coatings were used, 3-(trimethoxy silyl) propyl methacrylate
(TMSPM) and (3-aminopropyl)triethoxysilane (APTES). The devices were coated by
submerging the chip in a dilute solution of the silane. Initially, APTES was used to modify
the surface with amine groups, which would improve the hydrophilicity of the substrate.
However, the electrostatic interaction between the hydrogel and the amine groups were
significant enough to stop the hydrogel from peeling once the hydrogel became hydrated
by the buffers. Thus, we switched to TMSPM which contained a methacrylate group. Our
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hypothesis was the methacrylate surface would contribute to the crosslinking network
during the curing phase, and the physical crosslinking of the hydrogel onto the chip surface
would provide a much better adhesion even when the hydrogel was hydrated.
The results of the device coated with TMSPM and the hydrogel are shown in Figure
27. The hydrogel has significantly improved adhesion and remained on the chip after buffer
was added. It should be noted that the pH buffer was not removed in between each new
addition of buffer because the hydrogel did an effective job of absorbing it. After an initial
equilibration period, the device had a clear decrease in resistance with an increase in buffer
between pH 4-7. This decrease in pH is different than what was observed with the bare
GFET devices, which supported our original hypothesis that the graphene sensor could be
used to monitor the change in pH. The results suggest that the graphene could potentially
be sensing changes in the CS morphology as a function of pH. The results illustrate a
parabolic type of response over the entire pH range, which will require further
investigation. However, it is suspected that the pKa of the CS-MA-PEG hydrogel is around
pH 7-8, which would account for a change in morphology, resulting in an increase in device
resistance. The resistance only decreases once the hydrogel is given time to equilibrate at
a higher pH (Figure 27).
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pH vs Resistance Response of CS-MA-PEG
Hydrogels Coupled with GFET
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Figure 27. Change in resistance as a function of pH of a CS-MA-PEG GFET device
3.4 Thermogravimetric Analysis (TGA) of CS-MA-PEG hydrogels
TGA was utilized as a robust way to get qualitative information about the
morphology of the hydrogel at between pH 4-10. Our hypothesis was, if there was a change
in morphology around pH 7-8 (as suggested by the resistance measurements), then that
would be reflected by the bound/unbound water (weight loss) of the hydrogel. It is expected
that as the polymer undergoes a morphology change, for example, a coiled state vs
uncoiled, the amount of tightly bound water would change. Tightly bound water in this
experiment was measured as the weight loss between 100-150 °C. The hydrogels were
hydrated for at least 3 days and patted dry to remove any excess water. The results of this
experiment are shown in Figure 28.
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Figure 28. Unbound/bound water change of CS-MA-PEG hydrogels as a
function of pH
The CS-MA starting material and the hydrogel soaked in DI water were given for
comparisons, black and blue line, respectively. It should be noted that the average total
water content for all of the hydrogels was ~72%, which includes both bound and unbound
water. As hypothesized, the hydrogel that was soaked in pH 8 buffer had an unbound water
content of 67% and a bound water content of 5%. This is in stark contrast to every other
experiment where the unbound water ranged from 51-61 wt.% and bound water ranged
from 12-21 wt.%. This provided some evidence that there could be some morphology
change that contributed to the observed increase in resistance around pH 8.
3.5 Flow cytometry of treated and untreated HaCaT cells
Flow cytometry was used to elucidate cell cycle effects such as cell count and cell
size. Before cytometry, cells were cultured as described in 2.11. The cells were cultured
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for 6 days, and their confluence was validated through optical microscopy. After
confluency was achieved, the cells were treated with .5cm x .5cm x .25 cm segments of
CS-MA-PEG hydrogels. The hydrogels functioned as a scaffold for cell growth. Because
of the inherent porosity and high water content of the hydrogel, the cells were able to
permeate through the hydrogel. The cells were allowed to culture for 5 days, and cytometry
experiments were conducted on day 1,3, and 5 to assess the impact the hydrogel had on the
cell growth compared to the control. The cells were passed through a laser which counted
each disruption of its photon flow beam as cellular event. Each beam disruption caused
two scattering events to occur: forward and side scatter: Forward scatter (FSC) is the
transversally projected area of a cellular event, analogous to size. Whereas side scatter is
the axial projected area of a cellular event. Our hypothesis was that the treated cells (cells
exposed to the hydrogel) would present with larger characteristic sizes, when compared to
the control, and would proliferate faster, gauged through the number of cells found in a
microliter of cellular suspension, when compared to a control. Figure 29a and 29b
illustrates the cellular response of the hydrogel in context to the cell cycle.
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b.
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Figure 29 a-b. Flow Cytometry Results of Hydrogel’s Cell
Cycle response.
Figure 29a illustrates the effect of the hydrogel on cell size. From day 1 to day 5,
the cells experienced a 500% increase in size, when normalized to day 1. Figure 29b
illustrates the effect of the hydrogel on cell count, or proliferative capacity. For day 1, there
were 46% more treated cells than control cells. This trend continued for day 3 where there
were 129% more treated cells, and for day 5 were there were 69% more cells. Further, this
study also demonstrates that over a 5 day incubation period, the CS-MA-PEG hydrogel
does not have any cytotoxic effects on keratinocytes. That assumption, coupled with the
improved cell growth, provide strong evidence for our hydrogels potential application as
an effective wound dressing.
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4. Conclusions
In this research an attempt was made to examine the effects of a CS-MA-PEG hydrogel
on keratinocyte growth. Additional investigations of hydrogels as a potential coating on
graphene-based bio-sensors for continuous wound fluid pH monitoring were made.
Further, this research successfully synthesized the CS-MA precursor reported in literature
and established a protocol to reproduce formulations of CS-MA-PEG hydrogels with good
mechanical and optical properties; since there are no ASTM or ISO specifications.
It was shown that the hydrogel-based device could distinguish changes in pH. The
sensing kinetics and parameters of the combined hydrogel and graphene sensor are found
to be parabolic. Therefore, there is a need to investigate these kinetic phenomena in more
detail. A robust experiment using TGA was utilized to assess the morphological changes
at various pH levels to elucidate what could be causing the specific parabolic responses.
But, this data could only be used to speculate and vaguely support the hypothesis. Further
structural imaging techniques could be utilized to confirm the hydrogel morphology at
various pHs.
In terms of accelerating wound healing, this research demonstrated facilitated
keratinocyte growth cycles. The synthesized CS-MA-PEG hydrogel, after five days of
treatment imparted a five-fold increase in size to keratinocytes, when normalized to a day
1 control. Further, the hydrogels impacted keratinocyte proliferative capacity by increasing
the total number of treated cells per microliter by 46% on day 1, 129% on day 3, and 69%
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on day 5. These trends illustrate how keratinocytes, when they are cultured in the presence
of the hydrogel, deposit extracellular constituents, such as collagen type 1 and collagen
type 7, faster which will contribute to accelerated wound closure and stronger scar tissue
development. Further, through the acceleration of proliferation between day 1 and day 3,
the material has shown its utility in the crucial stages of wound healing.
Further examination into the genomic response of the material in a variety of cellular
domains, such as fibroblasts, keratinocytes, Langerhans cells, and endotheliocytes is
recommended.
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